ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Traditional LHRH Agonists Versus Newer Drugs

Howard M. Sandler, MD
Published: Tuesday, Mar 29, 2011

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, compares the efficacy of the mechanism of action for traditional LHRH agonists to newer androgen deprivation therapies. Sandler explains that newer therapies are capable of lowering testosterone levels to a degree that wasn't possible with LHRH agonists.

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, compares the efficacy of the mechanism of action for traditional LHRH agonists to newer androgen deprivation therapies. Sandler explains that newer therapies are capable of lowering testosterone levels to a degree that wasn't possible with LHRH agonists.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x